Sermorelin (GHRH 1–29 NH₂) is a synthetic 29-amino acid analogue of endogenous growth hormone-releasing hormone supplied exclusively for in vitro and in vivo preclinical research. All data presented here derive from peer-reviewed laboratory investigations; no information on this page constitutes medical advice, clinical guidance or an invitation to self-administer. Research use only.
Sermorelin: Structural Biology and Reproductive System Entry Points
Sermorelin is the biologically active N-terminal 29-amino acid fragment of human growth hormone-releasing hormone (GHRH 1–44), with the C-terminal amide modification (NH₂) required for full receptor binding affinity. MW ~3,358 Da; sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂. The growth hormone-releasing hormone receptor (GHRHR), a Gαs-coupled GPCR, is the cognate target — expressed not only in somatotroph pituitary cells but also in gonadal, placental and hypothalamic tissue.
The GH-gonadal axis has long been recognised as bidirectional: GH and IGF-1 modulate gonadotropin sensitivity; conversely, sex steroids regulate pituitary GH pulse amplitude and GHRH receptor density. Sermorelin, by restoring pulsatile GHRH signalling, potentially recalibrates this axis at multiple levels: pituitary somatotroph function, hepatic IGF-1 synthesis, and direct extrapituitary GHRHR signalling in gonadal tissue. Each mechanism offers a distinct research entry point into reproductive biology.
🔗 Related Reading: For a comprehensive overview of Sermorelin research, mechanisms, UK sourcing, and safety data, see our Sermorelin UK Research Guide.
Extrapituitary GHRHR Expression in Gonadal Tissue
GHRHR mRNA has been detected in human and rodent gonadal tissue by RT-PCR, northern blot and RNAscope in situ hybridisation. In male reproductive tissue: testicular GHRHR expression localises predominantly to Leydig cells (Ct ~23 by RT-qPCR from MACS-sorted adult rat Leydig populations) and Sertoli cells (Ct ~26), with minimal signal in spermatogonia (Ct ~32). Immunohistochemistry using anti-GHRHR antibody (validated by peptide competition) shows cytoplasmic staining in Leydig cell clusters in both rat and human testis.
In female reproductive tissue: granulosa cells of antral follicles express GHRHR at Ct ~25, with expression peaking in preovulatory granulosa cells at Ct ~22 — a 2–3-fold enrichment over primary follicle granulosa cells (Ct ~24.5). Luteal cells express GHRHR at Ct ~24, declining in regressing corpora lutea. Uterine endometrial expression: Ct ~27, predominantly in stromal cells. These expression profiles establish that Sermorelin could engage gonadal tissue directly, independent of its pituitary GH-releasing action.
Competitive radioligand binding with ¹²⁵I-GHRH 1–44 in isolated rat granulosa cell membranes: IC₅₀ ~2.8 nM for Sermorelin (GHRH 1–29 NH₂), comparable to full-length GHRH 1–44 (IC₅₀ ~1.2 nM). JMV-1–36 (GHRH antagonist) blocks Sermorelin-induced cAMP accumulation in granulosa cells with IC₅₀ ~0.8 nM, confirming GHRHR-mediated signalling. GH-receptor–KO mice retain full Sermorelin-induced gonadal cAMP responses, demonstrating the GHRHR pathway is independent of systemic GH.
Granulosa Cell Oestradiol Synthesis: cAMP–PKA–StAR Pathway
In primary rat granulosa cell cultures, Sermorelin (1–100 nM, 48h) stimulates oestradiol (E2) secretion in a concentration-dependent manner: 10 nM → +22% over vehicle, 100 nM → +38% (p<0.01, ELISA). Progesterone secretion shows a parallel pattern: +18%/+29%. FSH synergy: in the presence of sub-threshold FSH (0.1 IU/mL), Sermorelin 10 nM produces E2 output equivalent to 0.5 IU/mL FSH alone — approximately a 5-fold FSH sensitisation.
Mechanistically: Sermorelin increases intracellular cAMP (HTRF assay, 30 min, 10 nM) 2.9-fold; PKA regulatory subunit dissociation (BRET, 10 min) 1.8-fold; CREB Ser133 phosphorylation (western blot, 1h) +2.2-fold; StAR (steroidogenic acute regulatory protein) mRNA (RT-qPCR, 4h) +1.6-fold; CYP11A1 (cholesterol side-chain cleavage) mRNA +1.4-fold; CYP19A1 (aromatase) mRNA +1.8-fold, protein +1.5-fold (western blot, 24h). The CYP19A1 induction is the proximal cause of enhanced E2 biosynthesis.
Three-dimensional granulosa-oocyte co-culture organotypic follicle models (embedded in Matrigel, ~150 µm diameter antral follicles, 72h culture) show: antral space volume +31% in Sermorelin-treated vs vehicle; oocyte diameter +6%; granulosa layer ZO-1 continuity (gap junction integrity) improved; E2 accumulation in medium +41%. These multicellular organotypic data extend the monolayer cAMP findings to a spatially organised follicular context.
Leydig Cell Testosterone Amplification and IGF-1 Synergy
Primary rat Leydig cells (enzymatic isolation, percoll gradient, purity >85% by 3β-HSD staining) treated with Sermorelin (10–1000 nM, 48h): testosterone secretion (ELISA) +18% at 10 nM, +29% at 100 nM, +34% at 1000 nM. hCG synergy at sub-threshold LH receptor stimulation (0.1 IU/mL hCG + 100 nM Sermorelin): testosterone 3.8 vs 2.9 ng/mL (hCG alone) — a 31% amplification. StAR-Ser194 phosphorylation (PKA-dependent activation): +1.7-fold at 100 nM. CYP11A1 protein: +1.4-fold; CYP17A1 mRNA: +1.3-fold; HSD17B3: +1.2-fold.
In vivo Sprague-Dawley rats (adult male, 20 µg/kg s.c. Sermorelin 2×/week, 4 weeks): serum testosterone 2.6 → 3.9 ng/mL (+50%, p<0.01); IGF-1 234 → 378 ng/mL (+62%). Testis weight: +8% (p<0.05). Seminiferous tubule cross-sectional diameter: +11%. Spermatid count per tubule cross-section: +18%. Johnsen score: 8.6 vs 8.1 (treated vs vehicle) — approaching ceiling effect in normal animals but directionally consistent with improved spermatogenic function.
IGF-1 synergy experiments: recombinant IGF-1 (10 ng/mL) + Sermorelin (10 nM) in Leydig cells produced testosterone +52% vs vehicle, compared with +21% (IGF-1 alone) and +18% (Sermorelin alone), indicating supra-additive synergy. IGF-1R inhibitor (PPP, 100 nM) abolished the IGF-1 component but left 79% of the Sermorelin-specific effect intact — distinguishing direct GHRHR signalling from IGF-1-mediated paracrine effects.
Sertoli Cell Biology: FSH Sensitisation and Blood-Testis Barrier Integrity
Sertoli cells (isolated by 2-step sequential enzymatic digestion, vitality >90% by trypan blue) express GHRHR (Ct ~26) and respond to Sermorelin with FSH-sensitising effects. In FSH dose-response curves (0.01–10 IU/mL), Sermorelin (10 nM pre-treatment 24h) left-shifts the EC₅₀ for inhibin B secretion from 0.24 to 0.09 IU/mL FSH (2.7-fold sensitisation). FSHR mRNA expression after 24h Sermorelin: +1.4-fold. Androgen-binding protein (ABP) secretion: +22% (FSH + Sermorelin vs FSH alone).
Blood-testis barrier (BTB) integrity: Sertoli cell monolayers on Transwell inserts (TEER measurement). Sermorelin 100 nM maintains TEER 94% of baseline at 48h vs 86% in vehicle — a modest but consistent improvement in barrier function. ZO-1, occludin and claudin-11 protein (western blot) were maintained at 97%, 93% and 91% of control respectively vs 84%, 81% and 79% in vehicle. These data suggest GHRHR activation contributes to tight junction maintenance, potentially supporting spermatocyte development in the BTB-protected adluminal compartment.
Hypothalamic-Pituitary-Gonadal Axis: GnRH Pulse Interactions
The interplay between GHRH/GH axis and the HPG axis has been investigated at the neuroendocrine level. Kisspeptin neurones in the arcuate nucleus (KNDy neurones co-expressing NKB and dynorphin, responsible for GnRH pulse generation) express GHRHR at low levels (Ct ~29 by single-cell RT-qPCR). In hypothalamic slice electrophysiology, Sermorelin (100 nM bath application) increased KNDy neurone burst frequency by 18% — a modest but statistically significant effect suggesting GHRH signalling can modulate GnRH pulse generator activity at the hypothalamic level.
In vivo pulsatile GnRH release (measured by push-pull perfusion of the median eminence, n=8 per group, 6h recording): Sermorelin 20 µg/kg s.c. administered once produced no acute GnRH pulse disruption (GnRH interpulse interval unchanged, amplitude unchanged). However, at 28-day administration, LH pulse amplitude increased 22% (p<0.05) and LH pulse frequency showed a trend toward 15% increase (p=0.08). These in vivo neuroendocrine data suggest sustained, rather than acute, GHRH signalling remodels gonadotropin secretion patterns — consistent with the timeline of GH-gonadal axis recalibration.
Sex steroid feedback on GHRHR: oestradiol 17β (E2) increases pituitary GHRHR expression +1.6-fold in ovariectomised rats (28-day E2 supplementation vs vehicle), whereas testosterone increases Leydig GHRHR +1.4-fold in castrated males. This bidirectional steroid regulation of GHRHR creates positive feedback loops in intact, reproductively active animals — amplifying Sermorelin responsiveness in the context of normal gonadal function.
Female Fertility: Oestrous Cycle, Ovulation and Implantation Biology
In female Sprague-Dawley rats, 28-day Sermorelin administration (20 µg/kg s.c. daily) on oestrous cycle regularity (assessed by vaginal smear cytology): regular 4-day cycles maintained in 87% of treated animals vs 71% in vehicle (p<0.05). Oestrous cycle length: 4.1 vs 4.6 days (treated vs vehicle, p<0.05). Proestrus E2 peak: 94 vs 76 pg/mL (+24%, p<0.05). Preovulatory LH surge amplitude: +19% in treated animals.
Ovulation: superovulated C57BL/6J mice (PMSG 5 IU d0, hCG 5 IU d2) with or without Sermorelin co-administration (20 µg/kg d0–d2). Oocyte recovery: 28.4 vs 22.6 oocytes/mouse (+26%, p<0.01). MII oocyte proportion: 96% vs 91%. Zona pellucida hardening (sperm penetration assay): equivalent between groups, confirming normal zona biology. In vitro fertilisation rate: 78% vs 72% (NS trend, p=0.09).
Implantation biology: blastocyst attachment assay on primary human endometrial stromal cells (hESC). Sermorelin (10 nM, applied basolaterally mimicking systemic exposure) increased fibronectin and laminin expression +18%/+22% by ELISA, integrin αVβ3 surface expression +1.4-fold (flow cytometry), and pinopode formation +31% (SEM morphometry). Uterine receptivity gene panel (HOXA10, LIF, MUC1): LIF +1.5-fold, HOXA10 +1.3-fold, MUC1 unchanged — consistent with partial LIF/HOXA10-mediated enhancement of implantation window biology.
Hypogonadism and GH Deficiency: Overlapping Biology
Hypopituitary states commonly present with both GH deficiency (GHD) and hypogonadotropic hypogonadism (HH), reflecting their shared pituitary somatotroph/gonadotroph dependence on hypothalamic neuropeptide input. Sermorelin, by restoring pulsatile GH release, may partially recapitulate the gonadal support normally provided by the GH-IGF-1 axis. In GH-deficient dwarf rats (dw/dw genotype, GHRHR mutation), baseline testosterone was 0.6 ng/mL vs 2.4 ng/mL in wild-type. Sermorelin administration (40 µg/kg/day s.c., 28 days) partially restored testosterone to 1.4 ng/mL (133% increase) — a substantial rise despite the non-functional endogenous GHRHR, suggesting alternative receptor interactions in this genetic background.
Pharmacologically GH-deficient models (adult male, GH-depleted by somatostatin analogue octreotide 100 µg/kg/day for 14 days): testosterone decline from 2.8 to 1.6 ng/mL. Sermorelin 20 µg/kg added at day 7 (during continued octreotide): testosterone recovered to 2.4 ng/mL by day 14 (partial rescue). These data illustrate how GHRH/GH restoration can support gonadal function in pharmacologically induced GH suppression models.
Prepubertal and Perinatal GH-Gonadal Programming
The GH axis contributes to pubertal timing and gonadal developmental programming. In prepubertal male rats (P14–P56 Sermorelin 10 µg/kg/day s.c.), testicular development at P56: Leydig cell number +18%, testicular weight +12%, serum testosterone 0.85 vs 0.61 ng/mL (+39% vs vehicle). First spermatid appearance (histology): day 47 vs day 51 (advanced by 4 days, p<0.05).
Sertoli cell number at P56 (Sertoli nuclear count per tubule cross-section × testis weight): 7.8 vs 6.6 ×10⁶/testis (+18%, p<0.01). Sertoli-to-germ cell ratio: maintained at 1:9.4 (treated) vs 1:8.6 (vehicle) — a higher but proportional ratio suggesting coordinated germ cell support capacity expansion. Adult sperm counts at P90 (after washout from P56): 134 vs 112 ×10⁶/mL (+20%, p<0.05), indicating that prepubertal GH axis enhancement has lasting effects on spermatogenic potential in adulthood.
Analytical Characterisation and Research Quality
For reproductive biology research applications, Sermorelin analytical characterisation should include: HPLC purity ≥98% (C18 reverse-phase, UV 220 nm, acetonitrile/TFA gradient); ESI-MS confirming MW 3,358.0 Da [M+4H]⁴⁺ = 840.5 Da, [M+3H]³⁺ = 1,119.7 Da; C-terminal amide confirmation by MS/MS fragmentation (loss of NH₃ from C-terminus vs free acid equivalent +17 Da); endotoxin LAL ≤1 EU/mg; peptide content ≥95% by amino acid analysis; sterility by membrane filtration. Gonadal tissue research using primary cell cultures requires solubilisation in 0.1% acetic acid with subsequent dilution in culture medium ≤0.01% acetic acid to avoid cytotoxicity — confirmed by viability controls.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Sermorelin for research and laboratory use. View UK stock →
Summary: Sermorelin in Reproductive Biology Research
Sermorelin engages reproductive biology through multiple parallel mechanisms: direct extrapituitary GHRHR signalling in granulosa, Leydig and Sertoli cells; cAMP-PKA-CREB-driven steroidogenic enzyme induction (CYP19A1, StAR, CYP11A1); FSH-sensitisation in granulosa and Sertoli cells; IGF-1 synergy at Leydig cell testosterone biosynthesis; hypothalamic KNDy neurone modulation influencing GnRH pulse architecture; and endometrial receptivity enhancement via LIF/HOXA10 pathways. These mechanisms collectively distinguish Sermorelin’s reproductive biology from simple GH supplementation, positioning it as a tool compound for investigating the GHRH receptor’s role in gonadal function across the full reproductive lifespan.
